Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Different Financial Competing Interest Statements on Readers' Perceptions of Clinical Educational Articles

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02548312
Recruitment Status : Completed
First Posted : September 14, 2015
Results First Posted : June 12, 2019
Last Update Posted : June 12, 2019
Sponsor:
Information provided by (Responsible Party):
The BMJ

Study Type Interventional
Study Design Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Outcomes Assessor);   Primary Purpose: Other
Condition Healthy
Intervention Other: Variations of financial competing interest statements
Enrollment 1065
Recruitment Details  
Pre-assignment Details  
Arm/Group Title Dyspepsia Review- Competing Interest Statement 1 Gout Review- Competing Interest Statement 2 Dyspepsia Review- Competing Interest Statement 3 Dyspepsia Review- Competing Interest Statement 4 Gout Review- Competing Interest Statement 1 Dyspepsia Review- Competing Interest Statement 2 Gout Review- Competing Interest Statement 3 Gout Review- Competing Interest Statement 4
Hide Arm/Group Description

Honoraria & Travel:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.

Advisory board & consultancies:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.

Research funding:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals

None:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.

Honoraria & travel:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.

Advisory board & consultancies.

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.

Research funding:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals..

None:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.

Period Title: Overall Study
Started 133 133 134 133 133 133 133 133
Completed 100 90 96 87 99 93 93 91
Not Completed 33 43 38 46 34 40 40 42
Arm/Group Title Dyspepsia Review- Competing Interest Statement 1 Gout Review- Competing Interest Statement 2 Dyspepsia Review- Competing Interest Statement 3 Dyspepsia Review- Competing Interest Statement 4 Gout Review- Competing Interest Statement 1 Dyapepsia Review- Competing Interest Statement 2 Gout Review- Competing Interest Statement 3 Gout Review- Competing Interest Statement 4 Total
Hide Arm/Group Description

Honoraria & Travel:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.

Advisory board & consultancies:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.

Research funding:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals

None:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.

Honoraria & travel:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.

Advisory board & consultancies.

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.

Research funding:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals..

None:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.

Total of all reporting groups
Overall Number of Baseline Participants 100 90 96 87 99 93 93 91 749
Hide Baseline Analysis Population Description
[Not Specified]
Age, Continuous  
Mean (Full Range)
Unit of measure:  Years
Number Analyzed 100 participants 90 participants 96 participants 87 participants 99 participants 93 participants 93 participants 91 participants 749 participants
43.5
(23 to 79)
45.5
(24 to 72)
44.7
(25 to 75)
42.8
(24 to 67)
44.9
(25 to 75)
42.9
(24 to 76)
42.8
(24 to 67)
42.9
(24 to 76)
44
(23 to 79)
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 100 participants 90 participants 96 participants 87 participants 99 participants 93 participants 93 participants 91 participants 749 participants
Female
52
  52.0%
46
  51.1%
55
  57.3%
45
  51.7%
53
  53.5%
51
  54.8%
51
  54.8%
51
  56.0%
404
  53.9%
Male
48
  48.0%
44
  48.9%
41
  42.7%
42
  48.3%
46
  46.5%
42
  45.2%
42
  45.2%
40
  44.0%
345
  46.1%
Region of Enrollment  
Measure Type: Number
Unit of measure:  Participants
United Kingdom Number Analyzed 100 participants 90 participants 96 participants 87 participants 99 participants 93 participants 93 participants 91 participants 749 participants
100 90 96 87 99 93 93 91 749
Type of doctor  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 100 participants 90 participants 96 participants 87 participants 99 participants 93 participants 93 participants 91 participants 749 participants
Consultant
31
  31.0%
33
  36.7%
35
  36.5%
33
  37.9%
37
  37.4%
31
  33.3%
34
  36.6%
30
  33.0%
264
  35.2%
General practice
36
  36.0%
34
  37.8%
35
  36.5%
29
  33.3%
33
  33.3%
34
  36.6%
33
  35.5%
29
  31.9%
263
  35.1%
Junior doctor
33
  33.0%
23
  25.6%
26
  27.1%
25
  28.7%
29
  29.3%
28
  30.1%
26
  28.0%
32
  35.2%
222
  29.6%
1.Primary Outcome
Title The Readers' Level of Confidence in the Conclusions Drawn in the Article.
Hide Description Measured on a single-item 10-point Likert scale from (1) "not at all confident" to (10) "extremely confident". Higher scores indicate more confidence. Min score = 0, max score =10.
Time Frame Outcome measure will be assessed only at the time of the intervention (0 weeks). Readers will be asked to complete the study questionnaire immediately after reading the review article.
Hide Outcome Measure Data
Hide Analysis Population Description
One participant in the Group 'Gout review- competing interest statement 2', one in 'Dyspepsia review- competing interest statement 2', one in 'Dyspepsia- statement 3', and one in 'Gout- statement 4' did not respond to the question related to the primary outcome. Hence, for this outcome the numbers analyzed= 89, 92, 95 and 90, respectively.
Arm/Group Title Dyspepsia Review- Competing Interest Statement 1 Gout Review- Competing Interest Statement 2 Dyspepsia Review- Competing Interest Statement 3 Dyspepsia Review- Competing Interest Statement 4 Gout Review- Competing Interest Statement 1 Dyspepsia Review- Competing Interest Statement 2 Gout Review- Competing Interest Statement 3 Gout Review- Competing Interest Statement 4
Hide Arm/Group Description:

Honoraria & Travel:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.

Advisory board & consultancies:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.

Research funding:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals

None:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.

Honoraria & travel:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.

Advisory board & consultancies.

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.

Research funding:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals..

None:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.

Overall Number of Participants Analyzed 100 89 95 87 99 92 93 90
Mean (95% Confidence Interval)
Unit of Measure: score on a scale
6.2
(5.8 to 6.6)
7.0
(6.7 to 7.4)
6.1
(5.7 to 6.5)
6.4
(6.0 to 6.8)
7.1
(6.8 to 7.5)
6.2
(5.8 to 6.6)
7.4
(7.1 to 7.8)
7.4
(7.0 to 7.8)
2.Secondary Outcome
Title Importance of the Article.
Hide Description

Measured on a single-item 10-point Likert scale from (1) "not at all important" to (10) "extremely important". Higher scores indicate more importance. Min score = 0, max score =10.

Readers will be asked to complete the study questionnaire immediately after reading the review article.

Time Frame Outcome measure will be assessed only at the time of the intervention (0 weeks)
Hide Outcome Measure Data
Hide Analysis Population Description
One participant in the Group 'Gout review- competing interest statement 4' and one participant in 'Dyspepasia review- competing interest statement 3' did not respond to the question related to this outcome. Hence, for this outcome the numbers analyzed= 90 and 95 respectively (n=91 and n=96 in the participant flow chart).
Arm/Group Title Dyspepsia Review- Competing Interest Statement 1 Gout Review- Competing Interest Statement 2 Dyspepsia Review- Competing Interest Statement 3 Dyspepsia Review- Competing Interest Statement 4 Gout Review- Competing Interest Statement 1 Dyspepsia Review- Competing Interest Statement 2 Gout Review- Competing Interest Statement 3 Gout Review- Competing Interest Statement 4
Hide Arm/Group Description:

Honoraria & Travel:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.

Advisory board & consultancies:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.

Research funding:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals

None:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.

Honoraria & travel:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.

Advisory board & consultancies.

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.

Research funding:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals..

None:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.

Overall Number of Participants Analyzed 100 90 95 87 99 93 93 90
Mean (95% Confidence Interval)
Unit of Measure: score on a scale
6.3
(6.0 to 6.7)
6.4
(6.1 to 6.8)
6.3
(5.9 to 6.7)
6.3
(5.9 to 6.7)
6.9
(6.6 to 7.3)
6.5
(6.2 to 6.9)
6.7
(6.4 to 7.1)
7.0
(6.6 to 7.4)
3.Secondary Outcome
Title Interest in the Article.
Hide Description

Measured on a single-item 10-point Likert scale from (1) "not at all interesting" to (10) "extremely interesting". Higher scores indicate more interest. Min score = 0, max score =10.

Readers will be asked to complete the study questionnaire immediately after reading the review article.

Time Frame Outcome measure will be assessed only at the time of the intervention (0 weeks)
Hide Outcome Measure Data
Hide Analysis Population Description
One participant in the Group 'Dyspepsia review- competing interest statement 2', 'Dyspepsia review- statement 3', 'Gout review- statement 4' did not respond to the question related to this outcome. Hence, for this outcome the numbers analyzed= 92, 90 and 95 respectively (however n=93, 91 and 96 in participant flowchart).
Arm/Group Title Dyspepsia Review- Competing Interest Statement 1 Gout Review- Competing Interest Statement 2 Dyspepsia Review- Competing Interest Statement 3 Dyspepsia Review- Competing Interest Statement 4 Gout Review- Competing Interest Statement 1 Dyspepsia Review- Competing Interest Statement 2 Gout Review- Competing Interest Statement 3 Gout Review- Competing Interest Statement 4
Hide Arm/Group Description:

Honoraria & Travel:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.

Advisory board & consultancies:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.

Research funding:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals

None:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.

Honoraria & travel:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.

Advisory board & consultancies.

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.

Research funding:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals..

None:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.

Overall Number of Participants Analyzed 100 90 95 87 99 92 93 90
Mean (95% Confidence Interval)
Unit of Measure: score on a scale
5.9
(5.5 to 6.3)
6.2
(5.9 to 6.6)
5.8
(5.4 to 6.2)
5.8
(5.4 to 6.2)
6.7
(6.5 to 7.0)
6.0
(5.6 to 6.4)
6.5
(6.2 to 6.9)
7.0
(6.7 to 7.4)
4.Secondary Outcome
Title Number of Participants Who Are Extremely Likely to Change Practice on the Basis of the Article (Scored a "10"), for Those Currently Treating the Relevant Condition
Hide Description

Measured on a single-item 10-point Likert scale from (1) "not at all likely" to (10) "extremely likely". Higher scores indicate more likely to change practice. Min score = 1, max score =10.

Readers asked to complete the study questionnaire immediately after reading the review article.

Time Frame Outcome measure will be assessed only at the time of the intervention (0 weeks)
Hide Outcome Measure Data
Hide Analysis Population Description
Analysis only includes subset that indicated they currently treat gout/dyspepsia and own practice differed from recommendations given in the review.
Arm/Group Title Dyspepsia Review- Competing Interest Statement 1 Gout Review- Competing Interest Statement 2 Dyspepsia Review- Competing Interest Statement 3 Dyspepsia Review- Competing Interest Statement 4 Gout Review- Competing Interest Statement 1 Dyspepsia Review- Competing Interest Statement 2 Gout Review- Competing Interest Statement 3 Gout Review- Competing Interest Statement 4
Hide Arm/Group Description:

Honoraria & Travel:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.

Advisory board & consultancies:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.

Research funding:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals

None:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.

Honoraria & travel:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.

Advisory board & consultancies.

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.

Research funding:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals..

None:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.

Overall Number of Participants Analyzed 20 17 29 12 16 19 11 15
Measure Type: Count of Participants
Unit of Measure: Participants
0
   0.0%
4
  23.5%
2
   6.9%
1
   8.3%
1
   6.3%
2
  10.5%
2
  18.2%
3
  20.0%
Time Frame [Not Specified]
Adverse Event Reporting Description [Not Specified]
 
Arm/Group Title Dyspepsia Review- Competing Interest Statement 1 Gout Review- Competing Interest Statement 2 Dyspepsia Review- Competing Interest Statement 3 Dyspepsia Review- Competing Interest Statement 4 Gout Review- Competing Interest Statement 1 Dyspepsia Review- Competing Interest Statement 2 Gout Review- Competing Interest Statement 3 Gout Review- Competing Interest Statement 4
Hide Arm/Group Description

Honoraria & Travel:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.

Advisory board & consultancies:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.

Research funding:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals

None:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.

Honoraria & travel:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received honoraria and travel expenses from Jenka Pharmaceuticals for lecturing at a conference.

Advisory board & consultancies.

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received fees from Jenka Pharmaceuticals for consultancies and being an advisory board member.

Research funding:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has received research funding from Jenka Pharmaceuticals..

None:

We have read and understood the BMJ policy on declaration of interests and declare the following: DF is funded by a NIH clinician scientist award; SN receives no specific funding; JB has no competing interests.

All-Cause Mortality
Dyspepsia Review- Competing Interest Statement 1 Gout Review- Competing Interest Statement 2 Dyspepsia Review- Competing Interest Statement 3 Dyspepsia Review- Competing Interest Statement 4 Gout Review- Competing Interest Statement 1 Dyspepsia Review- Competing Interest Statement 2 Gout Review- Competing Interest Statement 3 Gout Review- Competing Interest Statement 4
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   --/--   --/--   --/--   --/--   --/--   --/--   --/--   --/-- 
Hide Serious Adverse Events
Dyspepsia Review- Competing Interest Statement 1 Gout Review- Competing Interest Statement 2 Dyspepsia Review- Competing Interest Statement 3 Dyspepsia Review- Competing Interest Statement 4 Gout Review- Competing Interest Statement 1 Dyspepsia Review- Competing Interest Statement 2 Gout Review- Competing Interest Statement 3 Gout Review- Competing Interest Statement 4
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   0/100 (0.00%)   0/90 (0.00%)   0/96 (0.00%)   0/87 (0.00%)   0/99 (0.00%)   0/93 (0.00%)   0/93 (0.00%)   0/91 (0.00%) 
Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 0%
Dyspepsia Review- Competing Interest Statement 1 Gout Review- Competing Interest Statement 2 Dyspepsia Review- Competing Interest Statement 3 Dyspepsia Review- Competing Interest Statement 4 Gout Review- Competing Interest Statement 1 Dyspepsia Review- Competing Interest Statement 2 Gout Review- Competing Interest Statement 3 Gout Review- Competing Interest Statement 4
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   0/100 (0.00%)   0/90 (0.00%)   0/96 (0.00%)   0/87 (0.00%)   0/99 (0.00%)   0/93 (0.00%)   0/93 (0.00%)   0/91 (0.00%) 
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Dr Sara Schroter
Organization: BMJ
Phone: 02073836744
EMail: sschroter@bmj.com
Layout table for additonal information
Responsible Party: The BMJ
ClinicalTrials.gov Identifier: NCT02548312    
Other Study ID Numbers: COI-RCT
First Submitted: September 8, 2015
First Posted: September 14, 2015
Results First Submitted: November 2, 2018
Results First Posted: June 12, 2019
Last Update Posted: June 12, 2019